Navigation Links
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
Date:6/10/2008

ng from blood cancers.

About Provid Pharmaceuticals Inc.

Provid is a drug discovery service company located in North Brunswick, New Jersey, that provides expert medicinal chemistry support to biotech and pharmaceutical industries, and to government labs, research foundations, and academic groups. The company also uniquely offers experimental due diligence (EXPEDD(TM)) to support decisions by academic technology transfer teams, venture investors, pharma and biotech portfolio management groups. The company has a strategic alliance with iNovacia AB in Stockholm that extends drug discovery capabilities via assay development, screening, and biophysical characterization. For more information, see http://www.providpharma.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
6. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
9. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... have devised a way to squeeze light into tighter ... new technology in the fields of optical communications, miniature ... in passing light through gaps 200 nanometers wide, about ... hair. A group of UC Berkeley researchers led by ...
... 30 Nektar,Therapeutics (Nasdaq: NKTR ) will announce ... 2008 on Wednesday, August 6, 2008, after the,close of ... will host a conference call to review the results,beginning ... (PT)., The press release and a live audio-only ...
... SAN DIEGO, July 30 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ... 30, 2008. For the second quarter of 2008, the Company ... compared with a net loss of,$26.4 million, or $(0.69) per ... the Company reported a net loss of $42.0 million, or ...
Cached Biology Technology:New technique to compress light could open doors for optical communications 2New technique to compress light could open doors for optical communications 3Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2Neurocrine Biosciences Reports Second Quarter 2008 Results 2Neurocrine Biosciences Reports Second Quarter 2008 Results 3Neurocrine Biosciences Reports Second Quarter 2008 Results 4Neurocrine Biosciences Reports Second Quarter 2008 Results 5Neurocrine Biosciences Reports Second Quarter 2008 Results 6Neurocrine Biosciences Reports Second Quarter 2008 Results 7Neurocrine Biosciences Reports Second Quarter 2008 Results 8Neurocrine Biosciences Reports Second Quarter 2008 Results 9
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... technical developments, and we will be increasingly moulded and changed ... future if we know what awaits us. So how can ... Applications Trends can provide sound assistance. It contains ... clear descriptions of all the main fields of technology. ...
... Sobrado, assistant professor of biochemistry ( http://www.biochem.vt.edu/faculty.php?lname=Sobrado&view=yes ) ... Tech, has received a Ralph E. Powe Junior ... that are essential for infection in two important ... presents the Powe award to faculty members who ...
... years ago: animals don,t pick their mates by pure chance ... factors. After decades of examining his work, experts agree that ... big question is, "What have we learned since then?" asks ... Adam Jones, an evolutional biologist who has studied Darwin,s work ...
Cached Biology News:Technology guide: Principles -- applications -- trends 2Powe Award supports research on how enzymes enable the pathogenicity of 2 human disease organisms 2Why do we choose our mates? Ask Charles Darwin, prof says 2
...
BD IMagnet 1 each...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: